ONCBeOne Medicines AG

1. Aug 26, 2026Key Differences between U.S. GAAP and PRC GAAP.Earnings release · press release
2. Aug 5, 2026BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates.Earnings release · press release
3. Jun 26, 2026As previously disclosed in the Quarterly Report on Form 10-Q filed by BeOne Medicines Ltd. (the “Company”) with the Securities and Exchange Commission on May 6, 2026, the Company is subject to ongoing tax audits that may result in liabilities which could be materially different from current estimates due to the …Other event · Form 8-K
4. Jun 11, 2026As previously disclosed in the definitive proxy statement for the 2026 Annual General Meeting of Shareholders (the “Annual Meeting”) of BeOne Medicines Ltd. (the “Company”) filed with the U.S. Securities and Exchange Commission on April 28, 2026 (the “Proxy Statement”), Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. …Director or officer change · Form 8-K
5. May 15, 2026On May 13, 2026, BeOne Medicines Ltd. announced that BEQALZI™ (sonrotoclax) has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, after at least two lines of systemic therapy, including a Bruton’s tyrosine …Other event · Form 8-K
6. May 6, 2026BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates.Earnings release · press release
7. Feb 26, 2026BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership.Earnings release · press release
8. Dec 19, 2025As previously disclosed in its Current Report on Form 8-K filed on November 19, 2025, BeOne Medicines Ltd. (the “Company”) entered into the Facilities Agreement (the “Facilities Agreement”), by and among (i) certain subsidiaries of the Company listed in the Facilities Agreement, as guarantors, (ii) The Hongkong and …Material agreement terminated · Form 8-K
9. Dec 18, 2025On December 17, 2025, BeOne Medicines Ltd. (the “Company”) appointed Dr. Lai Wang to serve as President, Global Head of Research and Development of the Company.Director or officer change · Form 8-K
10. Nov 19, 2025Entry into Facilities Agreement On November 13, 2025 (November 14, 2025 Hong Kong time), BeOne Medicines Ltd. (the “Company” and, together with its subsidiaries, the “Group”) entered into the Facilities Agreement (the “Facilities Agreement”), by and among (i) certain subsidiaries of the Company listed in the …Material agreement entered · Form 8-K
11. Nov 6, 2025BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.